Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
Status:
Terminated
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild
Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's
participation lasting approximately 18 months.